Doximity
NYSE: DOCS
$21.14 ▲ +0.72  (+3.53%)
At close: Jul 27, 2026 · 12:56 PM UTC
Financial Ratios
Market Cap3.95 Bn
P/E20.13
P/S6.12
Div. Yield0.00
Revenue Growth (1y) (Qtr)5.12
Add ratio to table…

About

Doximity, Inc. operates a digital platform that connects U. S. medical professionals and provides them with tools for communication, career management, and clinical workflow. The platform is free for verified physicians, nurse practitioners, physician assistants and medical students who join to access a professional network, a personalized newsfeed, and productivity applications. Members can create a detailed professional profile, exchange secure messages, schedule on call…

Read more ↓
Sector: Healthcare Industry: Health Information Services CIK: 0001516513

Investment Thesis

▲ Bull case
  • Doximity is positioned to capture a significant share of a multibillion-dollar TAM in AI-powered HCP paid search, leveraging its unique workflow integration and physician trust to convert incremental pharma budgets. Management highlighted that top 20 pharma companies have allocated minimum AI spend percentages (10-20%) of their budgets as part of compensation plans, indicating structural demand rather than speculative interest. The company’s AI search product, launched in late April, is already generating strong early interest and is designed to reach prescribers at the exact moment of clinical decision-making—a capability traditional paid search lacks. With 140 health systems (including 7 of the top 20 hospitals) having purchased the clinical AI suite and over 250 thousand prescribers granted HIPAA-compliant access, Doximity has achieved unprecedented distribution speed compared to its telehealth product, which took two years to reach similar milestones. This rapid adoption creates a defensible moat rooted in clinical workflow integration and data security, which newer entrants cannot easily replicate. Furthermore, the partnership with Aledade extends AI capabilities to independent primary care practices, expanding the addressable market beyond large health systems to the long tail of physicians who drive significant prescribing volume. The company’s AI investment year is not a near-term drag but a strategic foundation: while AI revenue contribution is forecasted to be minimal in fiscal 2027, the investments in R&D, compute, and peer review are building a differentiated, accurate product that wins head-to-head evaluations 2-to-1 against competitors. Given that workflow engagement grew 30% year-on-year in Q4 and AI usage among active prescribers nearly doubled from January to April, the underlying engagement flywheel is accelerating, setting the stage for monetization as regulatory reviews clear and pharma budgets unlock in the second half of the fiscal year. Doximity’s ability to outgrow the market over time is reinforced by its 50%+ revenue and engagement growth over the past three years, suggesting that even in a modest 4% market growth environment, its premium positioning and innovation velocity will drive share gains.
  • The company’s financial model demonstrates resilience and scalability, with free cash flow growth of 19% year-on-year to $317 million for fiscal 2026 and a strong balance sheet holding $749 million in cash and marketable securities. This financial firepower enables sustained investment in AI without compromising profitability, as evidenced by the maintenance of adjusted EBITDA margins in the high 40s or better despite elevated AI compute costs. Management’s guidance for fiscal 2027 reflects prudence, anticipating only 4% revenue growth at the midpoint, yet this conservative outlook does not fully capture the latent upside from AI search monetization, which is expected to ramp meaningfully in the fiscal back half. The disconnect between current guidance and potential upside is amplified by the shift toward shorter-term, higher-priced commitments from pharma clients seeking optionality—a dynamic that could ultimately improve unit economics. Doximity’s historical ability to convert engagement growth into revenue and free cash flow (with free cash flow per share more than doubling over three years) suggests that as AI engagement translates to paid search spend, the operating leverage will be substantial. The new leadership team, including CFO Matt Sonnefeld (with deep tech finance experience at LinkedIn, Atlassian, and DocuSign) and President Dr. Steven Zatz (former WebMD Medscape CEO), brings complementary expertise in scaling platform businesses and navigating pharma relationships, reducing execution risk in the AI commercialization effort. Critically, Doximity’s physician-first culture ensures that AI tools are designed to enhance—not disrupt—clinical workflows, a principle that has driven sustained adoption and positions the company to benefit from the long-term shift toward AI-augmented healthcare workflows without sacrificing trust or engagement.
▼ Bear case
  • Doximity’s near-term growth is constrained by persistent softness in the HCP digital pharma ad market, driven by elevated policy uncertainty and macroeconomic risks that are prompting clients to favor shorter-term commitments and delay upfront investments. Management acknowledged that visibility remains limited due to this environment, with only 65% of subscription-based revenue guidance booked at the start of the fiscal year—consistent with historical averages but reflective of cautious client behavior. The company’s guidance for just 4% revenue growth in fiscal 2027 implies a significant deceleration from the 13% year-on-year growth achieved in fiscal 2026, suggesting that the tailwinds from prior innovation cycles are fading. While AI engagement is accelerating, with nearly half of workflow users utilizing AI tools in Q4, the monetization of this engagement remains uncertain and deferred, as regulatory reviews and the need for clinical validation are slowing commercial rollout. The AI search product, though enthusiastically received by pharma executives, faces a nascent and regulated market where revenue contribution is explicitly forecasted to be minimal in the coming year, meaning that near-term growth will rely almost entirely on legacy products facing a challenging macro backdrop. Furthermore, the shift toward shorter-duration contracts—while potentially yielding higher prices—reduces predictability and increases the risk of revenue volatility, particularly if clients continue to prioritize optionality over commitment. The net revenue retention rate, though still strong at 109% on a trailing 12-month basis, showed sequential quarterly decline, hinting at potential weakening in expansion revenue from existing customers, a concern amplified by management’s avoidance of detailing specific therapeutic category trends despite analyst prompting.
  • Margin expansion is under pressure from rising AI-related costs, with non-GAAP gross margin declining to 89.3% in Q4 FY26 from 91.4% in the prior year period, driven by AI compute expenses that are outpacing overall workflow engagement growth. Although management frames this as a necessary investment, the sustained elevation of R&D and infrastructure spend—evidenced by a 57% year-on-year increase in non-GAAP R&D expense to $82.985 million for the full fiscal year—could weigh on profitability if AI monetization does not scale as anticipated. The company’s adjusted EBITDA margin guidance for fiscal 2027 of 49% represents a meaningful step down from the 55% achieved in fiscal 2026, reflecting expectations of continued investment without commensurate revenue contribution. This margin compression risk is exacerbated by the shift toward brand marketing and increased sales headcount to support the AI product launch, which Perry Scott Gold described as an intentional but costly effort to educate physicians and create noise around new features. Meanwhile, the competitive landscape in AI search is heating up, with numerous entrants vying for physician attention, and Doximity’s premium positioning may struggle to gain traction if clients shift toward lower-cost engagement options during periods of budget constraint—a dynamic management acknowledged but dismissed as unlikely to persist. The company’s reliance on pharma budgets, which are subject to regulatory and pricing pressures (e.g., IRA implications), introduces concentration risk, particularly if clients succeed in achieving more with less through internal analytics and consulting rather than external ad spend. Finally, the investigation by Halper Sadeh LLC into potential fiduciary breaches by officers and directors introduces an overhang that could distract management, trigger costly litigation, or lead to governance changes, even if ultimately unsubstantiated, adding non-operational volatility to the investment thesis.

Product and Service Breakdown of Revenue (2026)

Peer Comparison

Companies in the Health Information Services
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 VEEV Veeva Systems Inc 32.06 Bn34.059.66-
2 BTSG BrightSpring Health Services, Inc. 14.64 Bn47.281.072.50 Bn
3 HQY Healthequity, Inc. 8.29 Bn35.916.200.94 Bn
4 HNGE Hinge Health, Inc. 5.97 Bn-11.689.24-
5 TXG 10x Genomics, Inc. 5.95 Bn-262.409.31-
6 MMED MiniMed Group, Inc. 4.52 Bn-9.581.49-
7 WAY Waystar Holding Corp. 4.48 Bn35.533.871.47 Bn
8 DOCS Doximity, Inc. 3.95 Bn20.136.12-